Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol

Bernadette Cusack, Mona Boules, Beth M. Tyler, Abdul Fauq, Daniel J Mc Cormick, Elliott Richelson

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Neurotensin (NT) is a neuropeptide neurotransmitter in the central nervous system. It has been implicated in the therapeutic and in the adverse effects of neuroleptics. Activity of NT in brain can only be shown by direct injection of the peptide into that organ. However, we have developed a novel analog of NT(8-13), NT69L, which is active upon intraperitoneal (i.p.) injection. Like atypical neuroleptics, NT69L blocked the climbing behavior in rats, but not the licking and sniffing behaviors of a high dose (600 μg/kg) of the non-selective dopamine agonist apomorphine. Its blockade of climbing was very potent with an ED50 (effective dose at 50% of maximum) of 16 μg/kg. Both apomorphine and NT69L caused a long-lasting hypothermia, which was greater with the peptide but not synergistic in combination with apomorphine. The ED50 of NT69L for hypothermia was 390 μg/kg. NT69L (up to 5 mg/kg i.p.) did not produce catalepsy. However, when given before haloperidol, NT69L, but not clozapine, completely prevented catalepsy. When given after haloperidol, NT69L, but not clozapine, reversed haloperidol's cataleptic effects with an ED50 of 260 μg/kg. There was no significant difference between the ED50s for hypothermia and anticataleptic effects of NT69L. However, the ED50 for blocking the effects of apomorphine was significantly lower than the other two. These data suggest that NT69L may have neuroleptic properties in humans and may be useful in the treatment of extrapyramidal side effects caused by typical neuroleptics such as haloperidol. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)48-54
Number of pages7
JournalBrain Research
Volume856
Issue number1-2
DOIs
StatePublished - 2000

Fingerprint

Neurotensin
Apomorphine
Haloperidol
Peptides
Antipsychotic Agents
Hypothermia
Catalepsy
Clozapine
neurotensin (8-13)
neurotensin 69L
Dopamine Agonists
Intraperitoneal Injections
Neuropeptides
Neurotransmitter Agents
Central Nervous System
Injections

Keywords

  • Atypical neuroleptics
  • Catalepsy
  • Neurotensin receptor
  • Peptide analogs
  • Subtype 1

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. / Cusack, Bernadette; Boules, Mona; Tyler, Beth M.; Fauq, Abdul; Mc Cormick, Daniel J; Richelson, Elliott.

In: Brain Research, Vol. 856, No. 1-2, 2000, p. 48-54.

Research output: Contribution to journalArticle

Cusack, Bernadette ; Boules, Mona ; Tyler, Beth M. ; Fauq, Abdul ; Mc Cormick, Daniel J ; Richelson, Elliott. / Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. In: Brain Research. 2000 ; Vol. 856, No. 1-2. pp. 48-54.
@article{0ed35893cc864edd8d94a7119d060e86,
title = "Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol",
abstract = "Neurotensin (NT) is a neuropeptide neurotransmitter in the central nervous system. It has been implicated in the therapeutic and in the adverse effects of neuroleptics. Activity of NT in brain can only be shown by direct injection of the peptide into that organ. However, we have developed a novel analog of NT(8-13), NT69L, which is active upon intraperitoneal (i.p.) injection. Like atypical neuroleptics, NT69L blocked the climbing behavior in rats, but not the licking and sniffing behaviors of a high dose (600 μg/kg) of the non-selective dopamine agonist apomorphine. Its blockade of climbing was very potent with an ED50 (effective dose at 50{\%} of maximum) of 16 μg/kg. Both apomorphine and NT69L caused a long-lasting hypothermia, which was greater with the peptide but not synergistic in combination with apomorphine. The ED50 of NT69L for hypothermia was 390 μg/kg. NT69L (up to 5 mg/kg i.p.) did not produce catalepsy. However, when given before haloperidol, NT69L, but not clozapine, completely prevented catalepsy. When given after haloperidol, NT69L, but not clozapine, reversed haloperidol's cataleptic effects with an ED50 of 260 μg/kg. There was no significant difference between the ED50s for hypothermia and anticataleptic effects of NT69L. However, the ED50 for blocking the effects of apomorphine was significantly lower than the other two. These data suggest that NT69L may have neuroleptic properties in humans and may be useful in the treatment of extrapyramidal side effects caused by typical neuroleptics such as haloperidol. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Atypical neuroleptics, Catalepsy, Neurotensin receptor, Peptide analogs, Subtype 1",
author = "Bernadette Cusack and Mona Boules and Tyler, {Beth M.} and Abdul Fauq and {Mc Cormick}, {Daniel J} and Elliott Richelson",
year = "2000",
doi = "10.1016/S0006-8993(99)02363-X",
language = "English (US)",
volume = "856",
pages = "48--54",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol

AU - Cusack, Bernadette

AU - Boules, Mona

AU - Tyler, Beth M.

AU - Fauq, Abdul

AU - Mc Cormick, Daniel J

AU - Richelson, Elliott

PY - 2000

Y1 - 2000

N2 - Neurotensin (NT) is a neuropeptide neurotransmitter in the central nervous system. It has been implicated in the therapeutic and in the adverse effects of neuroleptics. Activity of NT in brain can only be shown by direct injection of the peptide into that organ. However, we have developed a novel analog of NT(8-13), NT69L, which is active upon intraperitoneal (i.p.) injection. Like atypical neuroleptics, NT69L blocked the climbing behavior in rats, but not the licking and sniffing behaviors of a high dose (600 μg/kg) of the non-selective dopamine agonist apomorphine. Its blockade of climbing was very potent with an ED50 (effective dose at 50% of maximum) of 16 μg/kg. Both apomorphine and NT69L caused a long-lasting hypothermia, which was greater with the peptide but not synergistic in combination with apomorphine. The ED50 of NT69L for hypothermia was 390 μg/kg. NT69L (up to 5 mg/kg i.p.) did not produce catalepsy. However, when given before haloperidol, NT69L, but not clozapine, completely prevented catalepsy. When given after haloperidol, NT69L, but not clozapine, reversed haloperidol's cataleptic effects with an ED50 of 260 μg/kg. There was no significant difference between the ED50s for hypothermia and anticataleptic effects of NT69L. However, the ED50 for blocking the effects of apomorphine was significantly lower than the other two. These data suggest that NT69L may have neuroleptic properties in humans and may be useful in the treatment of extrapyramidal side effects caused by typical neuroleptics such as haloperidol. Copyright (C) 2000 Elsevier Science B.V.

AB - Neurotensin (NT) is a neuropeptide neurotransmitter in the central nervous system. It has been implicated in the therapeutic and in the adverse effects of neuroleptics. Activity of NT in brain can only be shown by direct injection of the peptide into that organ. However, we have developed a novel analog of NT(8-13), NT69L, which is active upon intraperitoneal (i.p.) injection. Like atypical neuroleptics, NT69L blocked the climbing behavior in rats, but not the licking and sniffing behaviors of a high dose (600 μg/kg) of the non-selective dopamine agonist apomorphine. Its blockade of climbing was very potent with an ED50 (effective dose at 50% of maximum) of 16 μg/kg. Both apomorphine and NT69L caused a long-lasting hypothermia, which was greater with the peptide but not synergistic in combination with apomorphine. The ED50 of NT69L for hypothermia was 390 μg/kg. NT69L (up to 5 mg/kg i.p.) did not produce catalepsy. However, when given before haloperidol, NT69L, but not clozapine, completely prevented catalepsy. When given after haloperidol, NT69L, but not clozapine, reversed haloperidol's cataleptic effects with an ED50 of 260 μg/kg. There was no significant difference between the ED50s for hypothermia and anticataleptic effects of NT69L. However, the ED50 for blocking the effects of apomorphine was significantly lower than the other two. These data suggest that NT69L may have neuroleptic properties in humans and may be useful in the treatment of extrapyramidal side effects caused by typical neuroleptics such as haloperidol. Copyright (C) 2000 Elsevier Science B.V.

KW - Atypical neuroleptics

KW - Catalepsy

KW - Neurotensin receptor

KW - Peptide analogs

KW - Subtype 1

UR - http://www.scopus.com/inward/record.url?scp=0033975962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033975962&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(99)02363-X

DO - 10.1016/S0006-8993(99)02363-X

M3 - Article

C2 - 10677610

AN - SCOPUS:0033975962

VL - 856

SP - 48

EP - 54

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -